According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is ...

BACKGROUND: Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are approved for venous thromboembolism (VTE) prophylaxis. Which agent is superior remains controversial.

Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Early treatment with low-molecular-weight heparin (LMWH) reduces the risk for death in patients ...

The increased pregnancy rate at relatively advanced maternal age has led to higher rates of thromboembolic disease (TED), complicating pregnancy. A new paper discusses low-molecular-weight heparin ...

For patients with a variety of traumatic bone fractures, plain old oral aspirin provided just as good thromboprophylaxis as traditional low-molecular-weight heparin (LMWH) injections in the large ...

A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer No significant financial relationships to ...

Please provide your email address to receive an email when new articles are posted on . For prevention of venous thromboembolism after noncardiac surgery, direct oral anticoagulants may be preferred ...

Now reported in the Journal are the results of an international, multiplatform, randomized clinical trial that combined data from patients who were enrolled in one conventional randomized trial (ACTIV ...

According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is expected to grow at a CAGR of ...